Lifecore Biomedical to Be Acquired by Webster Equity Partners for $6.28 a Share Plus Contingent Payments
Total value can reach about $664 million if 2028–2030 targets are met.
/ 490 items
#XY Event-Driven Stocks↓
MediciNova Shares Fall After Mixed Phase 2 Results for Fatty Liver Drug MN-001
MediciNova fell after mixed Phase 2 data for MN-001. HDL rose, but week-24 liver fat and triglycerides missed significance in 40 patients.
Kodiak’s Zenkuda Meets Phase 3 Goal in Wet AMD, With More Than Half of Patients on Six-Month Dosing
Zenkuda was non-inferior to Eylea in vision, dried fluid quickly, and put 54% of wet AMD patients on 24-week dosing under strict treat-to-dryness rules.
Nektar Wins $90 Million Verdict Against Eli Lilly Over Rezpeg Partnership
California jury found Lilly breached good faith in the 2017 rezpeg deal and awarded Nektar $90 million plus interest. Lilly plans to appeal.
Prime Medicine Gets FDA Clearance to Start Human Testing of PM647 for Alpha-1 Antitrypsin Deficiency
First human data are due in 2027. This is not an approval; Beam remains ahead in patients.
Cullinan Stock Drop: Timeline Shift, Sector Selling, and Q4 Catalysts
A missed Q3 RA readout, sector pressure, and high short interest hit CGEM. Cash still funds operations into 2029. Next data: November and December.